Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02349802 · ClinicalTrials.gov registry record · Phase 1
Autoinjector Device Assessment Study
A Phase 1 study of Healthy Subjects, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 3,052
- Enrollment target
- 2
- Study locations
NCT02349802 is a Phase 1 study of Healthy Subjects that has completed, run by AstraZeneca. The registered enrollment target is 3,052 participants, above the 84-participant average among 69 other Healthy Subjects trials with a reported enrollment target (3533% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT02349802, a Phase 1 study of Healthy Subjects, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3,052 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.
Conditions Studied
Interventions
- DRUG Auto-injector with exenatide suspension
- DRUG Syringe with exenatide suspension
Study Locations (2)
Arizona
- Research Site - Tempe
Nebraska
- Research Site - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,052 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02349802
The ClinicalTrials.gov registry entry for NCT02349802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3,052 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 84-participant average among 69 other Healthy Subjects trials with a reported enrollment target (3533% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which Auto-injector with exenatide suspension is the first listed.
NCT02349802 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Nebraska.
Frequently Asked Questions
What is clinical trial NCT02349802 about?
NCT02349802 is a clinical study titled "Autoinjector Device Assessment Study". Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.
What is the current status of trial NCT02349802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3,052 participants. The study started on 2013-02. Estimated completion is 2013-12.
What conditions does trial NCT02349802 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT02349802?
The interventions under investigation include: Auto-injector with exenatide suspension (DRUG), Syringe with exenatide suspension (DRUG).
Who is sponsoring clinical trial NCT02349802?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02349802 being conducted?
This trial has 2 study locations across Arizona, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.